Couttas T, Jieu B, Rohleder C, Leweke F
Front Psychiatry. 2022; 13:885904.
PMID: 35711577
PMC: 9197191.
DOI: 10.3389/fpsyt.2022.885904.
Talib L, Costa A, Joaquim H, Pereira C, van de Bilt M, Loch A
Eur Arch Psychiatry Clin Neurosci. 2021; 271(8):1593-1599.
PMID: 33677687
DOI: 10.1007/s00406-021-01246-y.
Zhou X, Long T, Haas G, Cai H, Yao J
Front Neurosci. 2020; 14:784.
PMID: 32848558
PMC: 7403507.
DOI: 10.3389/fnins.2020.00784.
Yang G, Xu H, Zhang H, Yu Q, Wu Y, Shi J
PLoS One. 2016; 11(7):e0159584.
PMID: 27434078
PMC: 4951095.
DOI: 10.1371/journal.pone.0159584.
Cassoli J, Iwata K, Steiner J, Guest P, Turck C, M Nascimento J
Front Cell Neurosci. 2016; 10:52.
PMID: 26973466
PMC: 4776125.
DOI: 10.3389/fncel.2016.00052.
Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis.
Smesny S, Milleit B, Hipler U, Milleit C, Schafer M, Klier C
Mol Psychiatry. 2013; 19(3):317-24.
PMID: 23478748
DOI: 10.1038/mp.2013.7.
A structure-function mechanism for schizophrenia.
Vadakkan K
Front Psychiatry. 2013; 3:108.
PMID: 23293606
PMC: 3531891.
DOI: 10.3389/fpsyt.2012.00108.
Schizophrenia shows a unique metabolomics signature in plasma.
He Y, Yu Z, Giegling I, Xie L, Hartmann A, Prehn C
Transl Psychiatry. 2012; 2:e149.
PMID: 22892715
PMC: 3432190.
DOI: 10.1038/tp.2012.76.
Changes in erythrocyte membrane fatty acids during a clinical trial of eicosapentaenoic acid (EPA) supplementation in schizophrenia.
van Rensburg S, Smuts C, Hon D, Kidd M, van der Merwe S, Myburgh C
Metab Brain Dis. 2009; 24(4):659-72.
PMID: 19826937
DOI: 10.1007/s11011-009-9160-7.
Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation.
Martins-de-Souza D, Gattaz W, Schmitt A, Novello J, Marangoni S, Turck C
BMC Psychiatry. 2009; 9:17.
PMID: 19405953
PMC: 2684104.
DOI: 10.1186/1471-244X-9-17.
Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis.
Martins-de-Souza D, Gattaz W, Schmitt A, Rewerts C, Marangoni S, Novello J
J Neural Transm (Vienna). 2008; 116(3):275-89.
PMID: 19034380
DOI: 10.1007/s00702-008-0156-y.
Decreased phospholipase A2 activity in cerebrospinal fluid of patients with dementia.
Smesny S, Stein S, Willhardt I, Lasch J, Sauer H
J Neural Transm (Vienna). 2008; 115(8):1173-9.
PMID: 18584113
DOI: 10.1007/s00702-008-0081-0.
Role of calcium-independent phospholipase A2 in cortex striatum thalamus cortex circuitry-enzyme inhibition causes vacuous chewing movements in rats.
Lee L, Ong W, Farooqui A, Burgunder J
Psychopharmacology (Berl). 2007; 195(3):387-95.
PMID: 17768607
DOI: 10.1007/s00213-007-0912-y.
Association between BanI genotype and increased phospholipase A2 activity in schizophrenia.
Barbosa N, Junqueira R, Vallada H, Gattaz W
Eur Arch Psychiatry Clin Neurosci. 2007; 257(6):340-3.
PMID: 17629734
DOI: 10.1007/s00406-007-0736-0.
Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medications.
McNamara R, Jandacek R, Rider T, Tso P, Hahn C, Richtand N
Schizophr Res. 2007; 91(1-3):37-50.
PMID: 17236749
PMC: 1853256.
DOI: 10.1016/j.schres.2006.11.027.
Candidate gene polymorphisms among North Indians and their association with schizophrenia in a case-control study.
Semwal P, Prasad S, Varma P, Bhagwat A, Deshpande S, Thelma B
J Genet. 2003; 81(2):65-71.
PMID: 12532038
DOI: 10.1007/BF02715902.
Association studies of cytosolic phospholipase A2 polymorphisms and schizophrenia among two independent family-based samples.
Chowdari K, Brandstaetter B, Semwal P, Bhatia T, Deshpande S, Reddy R
Psychiatr Genet. 2002; 11(4):207-12.
PMID: 11807411
PMC: 5466560.
DOI: 10.1097/00041444-200112000-00005.
Dynamics of docosahexaenoic acid metabolism in the central nervous system: lack of effect of chronic lithium treatment.
Chang M, Bell J, Purdon A, Chikhale E, Grange E
Neurochem Res. 1999; 24(3):399-406.
PMID: 10215514
DOI: 10.1023/a:1020989701330.
Chronic lithium treatment decreases brain phospholipase A2 activity.
Chang M, Jones C
Neurochem Res. 1998; 23(6):887-92.
PMID: 9572678
DOI: 10.1023/a:1022415113421.
Intracerebral injection of phospholipase A2 inhibits dopamine-mediated behavior in rats: possible implications for schizophrenia.
Brunner J, Gattaz W
Eur Arch Psychiatry Clin Neurosci. 1995; 246(1):13-6.
PMID: 8773214
DOI: 10.1007/BF02191810.